Interruption to treatment with combined lopinavir/ritonavir therapy in HIV positive patients;Interrupción del tratamiento con la terapia combinada lopinavir/ritonavir en pacientes VIH+

Farmacia Hospitalaria

Volumn 31, Issue 4, 2007, Pages 206-211

  Sanfélix Gimeno, Gabriel ^a   Rocher Milla, A ^b   Roldan Garcia G ^a   Sanfelix Genoves J ^c   Pereiro Berenguer, I ^c   Peiro Moreno S ^a  

^a Generalitat Valenciana   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c Centro de Salud Nazaret   (Spain)

Author keywords

Antiretroviral therapy; Causes of interruption; HIV; Interruption; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PHARMACEUTICAL CARE; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

EID: 36348946314     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(07)75375-8     Document Type: Article

References (33)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998; 338: 853-60.
2. Hogg RS, O'Shaughnessy MV, Cataric N, Gataric N, Yip B, Craib K, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362: 22-9.
4. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Medicine 2005; 6: 99-106.
5. Messeri P, Lee G, Abramson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care 2003; 41: 512-21.
6. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17: 2227-36.
7. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P. Lopinavir-Ritonavir versus Nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
8. Benson CA, Deeks SG, Bran SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185: 599-607.
9. Abbott Laboratories. Kaletra (lopinavir-ritonavir) package insert. North Chicago, IL; 2000.
10. Agouron Pharmaceuticals, Inc. Viracept (nelfinavir) package insert. La Jolla, CA; 1999.
11. Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago, IL; 1999.
12. Glaxo Wellcom Inc. Agenerase (amprenavir) package insert. West Point PA; 1999.
13. Merk & Co. Inc. Crixivan (indinavir) package insert. West Point PA; 1999.
14. Roche Pharmaceuticals. Fortovase (saquinavir) package insert. Nutley, NJ; 1997.
15. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14: 499-507.
16. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185-94.
17. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy and its determinants. J Acquir Immune Defic Syndr Hum Retroviral 1999; 20: 290-4.
18. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23: 236-45.
19. Dorrucci M, Pezzotti P, Grisorio B, Minardi C, Muro MS, Vullo V, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: A comparision between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimenes. AIDS 2001; 15: 1733-6.
20. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37: 714-22.
21. Pedreira Vázquez I, Margusino Framiñán L, Pérez Fernández K, Martín Herranz I. Cambio del tratamiento antirretroviral en el patiente VIH. Farm Hosp 2004; (Supl. 1): 48-54.
22. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. February 4, 2002. Disponible en: URL: http://www.hivatis.org.
23. Le Moing V, Chene G, Leport C, Lewden C, Duran S, Garre M, et al; Antiproteases Cohorte (APROCO) Study Group. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 239-47.
24. Sommet A, Delpierre C, Cuzin L, Jaafar A, Marchou B, Massip P. Anti-retroviral treatment interruptions in HIV-infected adults: Causes, clinical, immunological and virological consequences. Rev Med Interne 2003; 24: 350-7.
25. Arribas Lopez JR, Sanz Baena S, Hernandez Albujar S, Lorenzo Hernandez A, Montes Ramirez ML, Palacios Munoz R, et al; Grupo de Estudio VIHVIR+. Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España. Med Clin (Barc) 2002; 119: 721-4.
26. Girard PM, Guiguet M, Bollens D, Goderel I, Meyohas MC, Lecomte I, et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. Clin Infect Dis 2000; 31: 987-94.
27. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-7.
28. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
29. Gulick RM, Mellors JW, Havlir D, Eron JJ, González C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
30. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15: F1-9.
31. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185: 599-607.
32. Barreiro P, Camino N, de Mendoza C, Valer L, Nunez M, Martin-Carbonero L, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002; 20: 438-43.
33. Parades R, Clotet B. Duración de las combinaciones de fármacos antirretrovirales. Med Clin (Barc) 2004; 122: 696-7.